

**CNS Research, Inc**  
**16 Haliburton Road**  
**E. Providence, RI 02916**

**Phone: 1-800-7076013**  
**Fax: 1-800-847-4332**  
**Email: [peter@cns-research.com](mailto:peter@cns-research.com)**

## **Peter J. Bellafiore , MD**

### **Certifications**

American Board of Psychiatry and Neurology – Neurology (Diplomate) 1998

### **Licensure**

Primary MD - 08924, RI

### **Academic Degrees**

MD - Internal Medicine, University of Vermont, College of Medicine, Burlington, VT 1991  
BS - Computer Science, Boston College, Boston, MA 1983

### **Residencies and Internships**

Chief Resident - Neurology, Medical Center Hospital of Vermont, VT 1993 - 1995  
Resident - Neurology, Medical Center Hospital of Vermont, VT 1992 - 1995  
Intern - Internal Medicine, Medical Center Hospital of Vermont, VT 1991 - 1992

### **Professional Societies**

American Academy of Neurology  
Rhode Island Neurologic Association

### **Experience**

Principal Investigator - CNS Research Inc., East Providence, RI 1998 - present  
Neurologist - Private Practice, Wakefield, RI 1995 - present

### **Appointments**

ICU Committee, South County Hospital, Wakefield, RI 1995 - present  
QA Committee, South County Hospital, Wakefield, RI 1995 - present  
TPA Protocol Committee, South County Hospital, Wakefield, RI 1995 - present  
Heparin Use Study, South County Hospital, Wakefield, RI 1995 - present  
Specialty Advisory Committee - Neurology, Blue Cross Blue Shield of Rhode Island

## Current Hospital Affiliations

South County Hospital - Wakefield, RI

## Research Affiliations:

CNS Research, Inc.  
450 Veterans' Memorial Parkway #11  
East Providence, RI 02914

CNS Research, Inc.  
360 Kingstown Rd Unit 102  
Narragansett RI 02882

CNS Research, Inc.  
16 Haliburton Road  
Rumford, RI 02916

## Research Activities

A Double-Blind, Placebo-Controlled Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Compound versus Placebo in the Relief of Pain in Diabetic Peripheral Polyneuropathy.

A Randomized, Double Blind, Parallel Group Study of the Safety and Efficacy of Latranal compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain

Phase III, "A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine"

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Adult Subjects with Migraine.

Evaluation of the Safety and Efficacy of Memantine in the Treatment of Chronic Pain in Patients with Diabetic Neuropathy.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Trial of Fidarestat 9 mg and 30 mg in Patients with Diabetic Polyneuropathy.

A Prospective, 26-Week, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) 3-12 mg/day in Patients with Mild to Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept (donepezil) Treatment.

An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy.

Phase III Study of the Efficacy and Safety of Alzhemed in Patients with Mild to Moderate Alzheimer's Disease.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis

AMDC-104-202: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Outpatients with Migraine Headache.

BiogenIdec: 109MS301: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.

Novartis Pharmaceuticals Protocol No.: CFTY720DUS01

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC).

BiogenIdec: 109MS303: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis.